NASDAQ
PMD

Psychemedics Corporation

Diagnostics & Research
Healthcare

Prices are adjusted according to historical splits.

Psychemedics Corporation Stock Price

Vitals

Today's Low:
$3.87
Today's High:
$3.97
Open Price:
$3.92
52W Low:
$3.85
52W High:
$6.5943
Prev. Close:
$3.95
Volume:
17037

Company Statistics

Market Cap.:
$22.68 million
Book Value:
1.589
Revenue TTM:
$23.62 million
Operating Margin TTM:
-14.72%
Gross Profit TTM:
$9.29 million
Profit Margin:
-8.02%
Return on Assets TTM:
-11.8%
Return on Equity TTM:
-17.99%

Company Profile

Psychemedics Corporation had its IPO on 1994-02-17 under the ticker symbol PMD.

The company operates in the Healthcare sector and Diagnostics & Research industry. Psychemedics Corporation has a staff strength of 133 employees.

Stock update

Shares of Psychemedics Corporation opened at $3.92 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.87 - $3.97, and closed at $3.89.

This is a -1.52% slip from the previous day's closing price.

A total volume of 17,037 shares were traded at the close of the day’s session.

In the last one week, shares of Psychemedics Corporation have slipped by -6.94%.

Psychemedics Corporation's Key Ratios

Psychemedics Corporation has a market cap of $22.68 million, indicating a price to book ratio of 2.427 and a price to sales ratio of 1.0671.

In the last 12-months Psychemedics Corporation’s revenue was $23.62 million with a gross profit of $9.29 million and an EBITDA of $-1749000. The EBITDA ratio measures Psychemedics Corporation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Psychemedics Corporation’s operating margin was -14.72% while its return on assets stood at -11.8% with a return of equity of -17.99%.

In Q2, Psychemedics Corporation’s quarterly earnings growth was a negative -30.2% while revenue growth was a negative 15%.

Psychemedics Corporation’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.34 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Psychemedics Corporation’s profitability.

Psychemedics Corporation stock is trading at a EV to sales ratio of 1.1133 and a EV to EBITDA ratio of 16.802. Its price to sales ratio in the trailing 12-months stood at 1.0671.

Psychemedics Corporation stock pays annual dividends of $0.28 per share, indicating a yield of 7.07% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$16.39 million
Total Liabilities
$5.64 million
Operating Cash Flow
$0
Capital Expenditure
$56000
Dividend Payout Ratio
0%

Psychemedics Corporation ended 2024 with $16.39 million in total assets and $0 in total liabilities. Its intangible assets were valued at $16.39 million while shareholder equity stood at $9.13 million.

Psychemedics Corporation ended 2024 with $0 in deferred long-term liabilities, $5.64 million in other current liabilities, 32000.00 in common stock, $-13729000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.45 million and cash and short-term investments were $2.45 million. The company’s total short-term debt was $1,366,000 while long-term debt stood at $154000.00.

Psychemedics Corporation’s total current assets stands at $8.23 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $4.01 million compared to accounts payable of $806000.00 and inventory worth $0.

In 2024, Psychemedics Corporation's operating cash flow was $0 while its capital expenditure stood at $56000.

Comparatively, Psychemedics Corporation paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$3.89
52-Week High
$6.5943
52-Week Low
$3.85
Analyst Target Price
$

Psychemedics Corporation stock is currently trading at $3.89 per share. It touched a 52-week high of $6.5943 and a 52-week low of $6.5943. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $4.64 and 200-day moving average was $5.06 The short ratio stood at 0.72 indicating a short percent outstanding of 0%.

Around 1995.2% of the company’s stock are held by insiders while 2526.6% are held by institutions.

Frequently Asked Questions About Psychemedics Corporation

The stock symbol (also called stock or share ticker) of Psychemedics Corporation is PMD

The IPO of Psychemedics Corporation took place on 1994-02-17

Similar Industry Stocks (Diagnostics & Research)

Last Price
Chg
Chg%
$0.34
0.04
+12.23%
$835.3
-15.4
-1.81%
$0.34
0
0%
$115.05
-1.75
-1.5%
$4912.85
-118.1
-2.35%
MPS Limited (532440)
$1431.45
-50.05
-3.38%
$181.95
-6.4
-3.4%
$1.09
0.02
+1.87%
$0.17
-0.02
-10.05%
9F Inc (JFU)
$2.64
0.05
+1.78%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, Fentanyl, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children’s drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

Address

289 Great Road, Acton, MA, United States, 01720